TG Therapeutics Earnings Loom With Stock (NASDAQ: TGTX) Outperforming Market

TG Therapeutics prepares to report its Q1 2025 financial results before this morning’s opening bell, with markets interested to see whether the firm can sustain its remarkable growth trajectory and justify a valuation that now stands at a significant premium to its peers.

The company has scheduled a conference call for 8:30 AM ET to discuss its first-quarter financial results and provide a business outlook for the remainder of the year. The call, hosted by Chairman and CEO Michael S. Weiss, follows the company’s recent pattern of outperformance, which has solidified investor optimism.

Analysts anticipate Q1 2025 earnings of $0.19 per share, a 371.4% year-over-year increase, with revenue projections of $118.5 million (up 86.7% from Q1 2024).

Investors will scrutinise management’s ability to sustain momentum against its ambitious 2025 revenue target of $540 million, which includes $525 million from U.S. BRIUMVI sales.

Other key points of interest on the call are expected to center around progress on BRIUMVI’s subcutaneous formulation, which could enable at-home administration and broaden patient access. Updates on the European launch of BRIUMVI in partnership with Neuraxpharm, alongside regulatory advancements for azer-cel, an allogeneic CAR T-cell therapy targeting autoimmune diseases, slated for Phase 1 trials in early 2025, will also be hot topics.

TG Therapeutics’ stock (NASDAQ: TGTX) has been a notable gainer YTD, with the 39.86% gains being added to by a 1.57% gain pre-market as we await the print. With the stock price rallying more than 160% over the past year, the company’s clinical success, and commercial execution, have set up a bullish trend that has significantly outperformed the broader market in the period.

For the technical analysts out there, the current TGTX setup also reinforces bullish sentiment. The stock’s 50-day and 200-day moving averages ($38.27 and $30.66, respectively) signal sustained upward momentum, while its Relative Strength Index (RSI) of 62.08 suggests moderate overbought conditions. Analysts highlight TG Therapeutics’ 88.3% gross margin and 3.7 quick ratio as indicators of solid financial health.

BRIUMVI’s Commercial Success and Market Penetration

BRIUMVI, a CD20-directed monoclonal antibody approved for relapsing forms of MS, has been the cornerstone of TG Therapeutics’ resurgence. In 2024, the drug generated $310 million in U.S. net revenue, marking a 250% year-over-year increase. This growth trajectory accelerated in Q4 2024, with quarterly net revenue reaching $103.6 million, outperforming initial guidance and prompting upward revisions to 2025 projections.

Key drivers of BRIUMVI’s success include:

1. Differentiated Dosing Regimen: BRIUMVI’s one-hour infusion time, shorter than competitors like Ocrevus, has resonated with clinicians and patients.
2. Patent Extension: The company secured patent protection for BRIUMVI through 2042, mitigating near-term generic competition risks.
3. European Expansion: Following regulatory approvals in the EU and UK, TG Therapeutics partnered with Neuraxpharm to commercialise BRIUMVI across Europe, leveraging Neuraxpharm’s neurology-focused infrastructure.

The drug’s adoption is further evidenced by over 1,250 new prescriptions in Q1 2024, representing a 25% quarter-over-quarter increase. Analysts at B. Riley have raised their price target for TGTX to $53, citing BRIUMVI’s “blockbuster potential” and the company’s operational efficiency.

TG Therapeutics’ transition to profitability has been a pivotal narrative. For full-year 2024, the company reported net income of $23.4 million, a stark reversal from prior losses. This turnaround was fueled by BRIUMVI’s commercial success and disciplined cost management, with R&D and SG&A expenses totaling $94.3 million and $154.3 million, respectively.

🟩 The Bull Case

• BRIUMVI’s rapid commercial adoption and patent protection through 2042 underpin sustained revenue growth.
• Pipeline diversification with subcutaneous BRIUMVI and azer-cel offers new growth levers.
• Transition to profitability and strong gross margins support operational resilience.
• Institutional backing and consistent earnings beats reinforce investor confidence.
• Technical momentum and bullish analyst price targets suggest further upside potential.

🟥 The Bear Case

• Elevated valuation metrics (P/E and P/S ratios) leave little room for error.
• Heavy reliance on BRIUMVI; setbacks in uptake or competition from rivals like Ocrevus could derail growth.
• Regulatory delays or adverse trial results for pipeline assets may trigger sharp corrections.
• Sector-wide volatility and macroeconomic headwinds could pressure biotech valuations.

Pipeline Expansion and Long-Term Growth Catalysts

The company is developing a subcutaneous version of BRIUMVI to enable at-home administration, potentially capturing patients averse to intravenous infusions. Early-stage trials have demonstrated comparable efficacy to the IV formulation, with a Phase 3 trial expected in late 2025.

TG Therapeutics acquired azer-cel, an allogeneic CAR T-cell therapy targeting B-cell-driven autoimmune disorders, in 2024. Preclinical data showed promising efficacy in lupus and myasthenia gravis models, with Phase 1 trials slated for early 2025. Success here could position TGTX as a leader in next-generation autoimmune therapies.

The company is also exploring BRIUMVI’s efficacy in non-MS indications, including primary progressive MS (PPMS) and neuromyelitis optica spectrum disorder (NMOSD). Positive data from the ENHANCE Phase 3b trial presented at ACTRIMS 2025 underscored BRIUMVI’s safety profile in diverse patient populations.

While macroeconomic and competitive risks persist, TG Therapeutics’ combination of commercial traction and innovative pipeline investments underscores its potential to deliver sustained shareholder value.

As Michael S. Weiss noted, “Our accomplishments in 2024 have laid a foundation for continued success in 2025 and beyond”.

TG Therapeutics stands at a pivotal juncture, with its Q1 2025 earnings call poised to validate, or challenge, the bullish narrative that has defined the past year. While the company’s commercial execution and pipeline depth offer compelling upside, the premium valuation and inherent biotech risks demand vigilant monitoring.